

AACI (Pittsburgh, Pa.)

Dr. Michael A. Caligiuri, Director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute, stepped into a new two-year term recently as President of the Association of American Cancer Institutes (AACI). Prior to joining OSUCCC-James 11 years ago, Dr. Caligiuri, a prominent figure in the fields of immunology, leukemia and lymphoma research, was affiliated with Roswell Park Cancer Institute in Buffalo, NY.

AACR (Philadelphia, Pa.)

Margaret Foti, PhD, MD (h.c.), CEO of the American Association for Cancer Research (AACR), was recognized for her leadership in the worldwide cancer community with the inaugural European CanCER Organisation Award for Lifetime Achievement at the ECCO 15-34th ESMO Multidisciplinary Congress. AACR President-elect Elizabeth H. Blackburn, PhD, and AACR member Carol W. Greider, PhD, won the Nobel Prize in Physiology or Medicine, for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase. Michael J. Burton was named as Chief Development Officer and Executive Director of the AACR Foundation.

ASCO (Alexandria, Va.)

The American Society of Clinical Oncology (ASCO) plans to hold its Annual Meeting at Chicago's McCormick Place for the next 10 years, beginning with the 46th Annual Meeting from June 4-8, 2010.

AMGEN Inc. (Thousand Oaks, Calif.)

Amgen, Novartis, and GlaxoSmithKline all emerged as winners of prestigious Prix Galien USA awards for their respective products. Amgen won the Prix Galien USA Best Biotechnology Product award for Nplate®, GlaxoSmithKline won the Best Biotechnology Product award for Promacta®, and Novartis won the Best Pharmaceutical Product award for Gleevec®.

AVEO PHARMACEUTICALS Inc. (Cambridge, Mass.)

William J. Slichenmyer, MD, ScM, was appointed to the position of Chief Medical Officer (CMO). Dr. Slichenmyer most recently served as CMO at Merrimack Pharmaceuticals and was formerly at Pfizer, Inc. Dr. Slichenmyer joins Aveo as the company moves its lead oncology drug candidate, tivozanib, into Phase 3 clinical development for renal cell cancer. Robert C. Young, MD, President of RCY Medicine and the former Chancellor of Fox Chase Cancer Center in Philadelphia, Pa., joined Aveo's Board of Directors.

BIONOVO Inc. (Emeryville, Calif.)

Dr. Debu Tripathy, Professor of Medicine and Co-Director of the Women's Cancer Program at the University of Southern California, was appointed to Bionovo's Medical Advisory Board. Dr. Tripathy joins the board as the company seeks to advance its novel, oral drug Bezielle® for metastatic breast cancer through clinical development.

DENDREON Corp. (Seattle, Wash.)

Ian Clark and Pedro Granadillo were elected to the Board of Directors. Clark, who currently heads global product strategy and is Chief Marketing Officer at Roche, Pharma Division, will become CEO and head of North American commercial operations of Roche's Genentech unit on January 1, 2010. Granadillo, now retired, had been Eli Lilly & Co.'s top executive for both global manufacturing and human resources. The appointments were made as the company gears up for the anticipated FDA approval and launch of its prostate cancer vaccine Provenge® in 2010.

ELI LILLY & Co. (Indianapolis, Ind.)

In conjunction with the announcement of a new operating model to speed innovative medicines to patients, the company named leaders of its five business units including John H. Johnson as head of the oncology business unit. Johnson currently serves as CEO of ImClone Systems, a wholly-owned subsidiary of Lilly. Currently, one-third of Lilly's pipeline is composed of molecules to treat various forms of cancer.

GENENTECH Inc. (South San Francisco, Calif.)

Genentech loyalists take note: The biotech's name and famous blue logo will still be ubiquitous even after Roche's \$47 billion buyout. *The Wall Street Journal's Health Blog* recently reported that Roche plans to rebrand all its U.S. medicines as Genentech including nonbiotech drugs. Product packaging will be changed to remove the Roche logo and Genentech's name will show up in the drugs' individual Web sites. In other Roche-Genentech related news, the Swiss company named Pascal Soriot, the chief architect of its integration with Genentech, to head its drugs business. Soriot will replace William Burns as head of its pharma division at the end of the year.

IMMUNOGEN Inc. (Waltham, Mass.)

Peter Williams was appointed as Vice President, Business Development. Williams joins ImmunoGen with over twenty years of business development, deal negotiation and technology in- and out-licensing experience. He was most recently Senior Director of Business Development at Alnylam Pharmaceuticals, Inc.

THE JOHN THEURER CANCER CENTER (Hackensack, N.J.)

David H. Vesole, MD, PhD, FACP, joined the Multiple Myeloma Division at The John Theurer Cancer Center of Hackensack University Medical Center as Co-division Chief, Myeloma, and Director of Research, Myeloma Division and will work with Division Chief David S. Siegel, MD, PhD. Dr. Vesole, an expert in stem cell transplant therapy for the treatment of multiple myeloma, previously served as Director of the Bone Marrow Transplant Program at Loyola University Chicago-Stritch School of Medicine. The Cancer Center's Multiple Myeloma Division is one of only a few facilities in the U.S. to offer specialized expertise in the diagnosis, treatment, and management of multiple myeloma.

MICROMET Inc. (Bethesda, Md.)

Jan Fagerberg, MD, PhD, was appointed as Senior Vice President and CMO effective November 1. Dr. Fagerberg was previously employed with F. Hoffmann-La Roche as Therapeutic Area Expert Oncology in Global Drug Development. During his tenure at Roche, he was responsible for the global clinical development of Xeloda®, and for the clinical development programs of Avastin® outside the U.S. Dr. Fagerberg joins Micromet from TopoTarget, where he was Medical Director.

ONYX PHARMACEUTICALS Inc. (Emeryville, Calif.)

Onyx announced it would buy cancer drug developer Proteolix, Inc. in a deal that could be worth as much as \$851 million. The company will pay \$276 million upfront to gain Proteolix's cancer drug candidate carfilzomib, which is being tested for multiple myeloma, non-Hodgkin's lymphoma, and solid tumors. Onyx said the purchase would help the company expand into the lucrative \$16 billion blood cancers market. Proteolix is conducting midstage clinical trials of carfilzomib as a stand-alone treatment for multiple myeloma. The deal is expected to close in the fourth quarter of 2009.

OXIGENE Inc. (South San Francisco, Calif.)

John A. Kollins resigned as CEO and as a member of the Board of Directors after only a year on the job. **Peter Langecker, MD, PhD**, Executive Vice President and Chief Development Officer, will serve as Interim CEO while the company conducts a search for a replacement for Kollins. The company also announced that it would acquire VaxGen in a stock-for-stock merger. The transaction is expected to close in the first quarter of 2010.

PEREGRINE PHARMACEUTICALS Inc. (Tustin, Calif.)

Noted cancer researcher **Bruce Chabner, MD**, will serve as a clinical advisor on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the Clinical Director of Massachusetts General Hospital (MGH) Cancer Center, Chief of Hematology and Oncology at MGH and a Professor of Medicine at Harvard Medical School. Bavituximab is currently being evaluated in Phase 2 clinical trials for advanced breast and lung cancer. **Dr. Robert Garnick**, formerly the Senior Vice President of Regulatory, Quality and Compliance at Genentech, joined Peregrine as the head of regulatory affairs. Dr. Garnick will be responsible for overseeing the company's interactions with the FDA and regulatory agencies around the world.

SEATTLE GENETICS Inc. (Bothell, Wash.)

Bruce J. Seeley was named Executive Vice President, Commercial. He will lead marketing and sales functions for the planned 2011 product launch of brentuximab vedotin, the company's first marketed product. Seeley was most recently at Genentech BioOncology as Senior Director for Herceptin® and T-DM1 marketing. **Kirk D. Schumacher** was promoted to Vice President, Legal Affairs and Compliance, and General Counsel.

SHANDS CANCER CENTER (Gainesville, Fla.)

Paul Okunieff, MD, was named Director of the University of Florida Shands Cancer Center and Chairman of the UF College of Medicine Department of Radiation Oncology, effective December 1. Dr. Okunieff is currently a Professor in Radiation Oncology and Chair of the Department of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. Dr. Okunieff succeeds both **Joseph Simone, MD**, who headed the Cancer Center in 2009, and **Robert Amdur, MD**, Professor and Interim Chair of the Department of Radiation Oncology since 2006.

SOLIGENIX Inc. (Princeton, N.J.)

Dor BioPharma, Inc. completed a corporate name change to Soligenix, Inc. and the company's shares of common stock began trading under the new ticker symbol "SGNX" on September 30. Soligenix's address and contact numbers will remain the same. The new web address is www.soligenix.com. The company's lead product, orBec® is being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation.

SUPERGEN Inc. (Dublin, Calif.)

David Bearss, PhD, resigned as Chief Scientific Officer, effective on October 16. He will continue an association with the company as a long-term biology consultant, in addition to retaining his Scientific Advisory Board membership. Dr. Bearss will return to academic cancer research, as Co-director of the Center for Investigational Therapeutics of Huntsman Cancer Institute at the University of Utah. **Michael McCullar, PhD, MBA**, Vice President, Strategy and Operations, will resume his position as Head of Discovery Operations.

US ONCOLOGY Inc. (The Woodlands, Tex.)

Roger W. Anderson, DrPH, was named Chief Pharmacy Officer and will oversee pharmacy services for US Oncology and its affiliated practices.

YALE CANCER CENTER (New Haven, Conn.)

Kevin Vest, PT, MBA, FACHE, was recently hired as Deputy Director of Clinical Affairs and Administration. Vest joins Yale Cancer Center from Massachusetts General Hospital Cancer Center where he served as Administrative Director for Hematology/Oncology and Finance. **Chad A. Ellis, PhD**, was appointed as Deputy Director for Research. Dr. Ellis joins Yale Cancer Center from the National Cancer Institute (NCI) where he was a Program Director for the Cancer Centers Program. **NIC**

»» READY TO GET GREEN?

THE OBR E-JOURNAL HAS LAUNCHED:

- MORE TIMELY
- MORE CONTENT
- LESS TREES

SUBSCRIBE TODAY AT ONCBIZ.COM

O_bR green